Clinical trials
Breast Cancer - Infiltrating Ductal Carcinoma clinical trials
Below are recruiting breast cancer - infiltrating ductal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 248 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT04072653Recruiting
Sentinel node biopsy versus watchful waiting after PET
This trial studies whether taking a sample from the sentinel lymph node (a first lymph node that can be involved) improves care compared with observation, after a breast cancer PET scan of the armpit area. It may help people with certain early breast cancers avoid unnecessary procedures if the lymph nodes look negative on scans.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05217966Recruiting
Radiation before possible breast surgery for early ER-positive cancer
This study gives radiation to the breast before surgery to see if some people can safely delay or even skip surgery. It targets women with a small, node-negative, ER-positive breast cancer with low genetic risk.
Montreal, QuebecAges 50 years+ - NCT05704166RecruitingPhase 2
Pirfenidone to prevent lung injury after breast radiation
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
Fuzhou, FujianAges 18–75 - NCT06078384RecruitingPhase 2
Pembrolizumab and chemo for early-stage triple-negative breast cancer
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
AmiensAges 18 years+ - NCT06336070Recruiting
Power training for metabolic health in postmenopausal cancer survivors
This trial compares two types of exercise—muscle power training and metabolic power training—to see which better improves your body's ability to use energy and control heart function. You may qualify if you are a postmenopausal woman who has had breast cancer and is not currently active.
Valencia, ValenciaAges 35–75 - NCT06522568Recruiting
Mammogram decision help for women in rural areas
This trial tests a shared decision-making tool to help women aged 39-49 talk with their doctor about whether to get a mammogram. It aims to make the choice clearer for patients in rural settings.
Keene, New HampshireAges 39–49 - NCT06627712RecruitingPhase 3
SBRT with immunotherapy and chemo for early-stage triple-negative breast cancer
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Sichuan, ChengduAges 18–65 - NCT06703567Recruiting
Helping patients understand gene test results for breast cancer
This study tests a tool to help people newly diagnosed with early-stage breast cancer better understand their gene test results. It is for patients who haven't yet decided about chemotherapy and want to learn more about their options.
MilanAges 18 years+ - NCT07426809Recruiting
A study to improve lumpectomy surgery with real-time imaging
This study tests a new imaging tool that helps surgeons see cancer margins in real time during a lumpectomy, aiming to reduce the need for a second surgery. It is for women with early-stage breast cancer who are planning a lumpectomy.
Beaumont, DublinAges 18 years+ - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06079346RecruitingPhase 2/Phase 3
New drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
Detroit, MichiganAges 18 years+ - NCT07255404RecruitingPhase 2
Testing pumitamig with chemotherapy for untreated pancreatic cancer
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
Bedford ParkAges 18 years+ - NCT07259317RecruitingPhase 2
Relacorilant plus chemo for metastatic pancreatic cancer
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
Scottsdale, ArizonaAges 18 years+ - NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT05236972RecruitingPhase 3
PD-1 antibody after colon cancer surgery for dMMR stage III
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
GuangzhouAges 18–75 - NCT06940518RecruitingPhase 2
Ivonescimab for advanced clear cell kidney cancer
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06041516RecruitingPhase 1
New drug ADCT-701 for neuroendocrine and nerve tumors
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
Bethesda, MarylandAges 18–120 - NCT07085572RecruitingPhase 2
Cemiplimab for maintenance in adrenocortical cancer
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
Brescia, BresciaAges 18 years+ - NCT05601505RecruitingPhase 2
DNA blood test–guided treatment before rectal cancer surgery
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
Beijing, Beijing MunicipalityAges 18–75 - NCT06120387Recruiting
Radiation after kidney-sparing surgery for high-risk ureteral cancer
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
BeijingAges 18 years+ - NCT05582122RecruitingPhase 2
Tracking HPV16 DNA in blood to spot cancer coming back
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
Saint-Denis, La RéunionAges 18 years+ - NCT07364357RecruitingPhase 1
Study of CREPT-618 for advanced liver cancer
This phase 1 trial tests a new drug called CREPT-618 for people with advanced liver cancer that hasn't responded to standard treatments. The drug is designed to target cancer cells with specific markers (CREPT and ASGPR), so only patients whose tumors have these markers can join.
BeijingAges 18–75 - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Breast Cancer - Infiltrating Ductal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer - infiltrating ductal carcinoma?
- Yes. Clin2 currently lists 248 recruiting breast cancer - infiltrating ductal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer - infiltrating ductal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer - infiltrating ductal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.